Milestones

2015
Threshold reports data on TH-4000 supporting plans for Phase 2 clinical trials.
Threshold completed an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock; net proceeds to Threshold were approximately $28.1 million.

2014
Threshold reports encouraging initial data on combination of evofosfamide plus bortezomib plus dexamethasone in patients with relapsed/refractory multiple myeloma reported at ASH 2014.
Threshold announces its Phase 3 trial of TH-302 in patients with advanced soft tissue sarcoma will continue as planned following protocol-specified interim analysis.
Threshold initiates 440-patient, randomized, double-blind, placebo-controlled trial of TH-302 in combination with pemetrexed in advanced non-squamous non-small cell lung cancer.
Threshold presents clinical data on TH-302 in glioblastoma and relapsed/refractory multiple myeloma at ASCO.
Threshold CEO, Barry Selick, Ph.D., named as finalist for European Inventor Award.
Threshold acquires investigational hypoxia PET imaging agent [18F]-HX4 from Siemens Healthcare; Threshold initially intends to develop [18F]-HX4 as a companion diagnostic to its hypoxia-targeted therapeutics.

2013
Threshold announces target enrollment of 620 patients achieved in pivotal Phase 3 Trial of TH-302 in advanced soft tissue sarcoma.
Threshold reports early clinical data on combinations of TH-302 with antiangiogenic agents in advanced solid tumors. Preliminary data signal that TH-302 in combination with bevacizumab may have activity in patients with glioblastoma following single-agent bevacizumab failure.
Threshold initiates Phase 2 trial of TH-302 in patients with advanced melanoma.
Threshold expands target enrollment number in Phase 3 trial of TH-302 in soft tissue sarcoma, intending to strengthen the ability of the study to detect a clinically meaningful and statistically significant effect of TH-302 on overall survival. FDA agrees to the amendment under the existing Special Protocol Agreement.
Initial data from two Phase 1/2 trials of TH-302 demonstrate responses in patients with multiple myeloma and in patients with renal cell carcinoma and gastrointestinal stromal tumors.
Threshold acquires investigational hypoxia PET imaging agent [18F]-HX4 from Siemens Healthcare; Threshold initially intends to develop [18F]-HX4 as a companion diagnostic to its hypoxia-targeted therapeutics.
Merck KGaA, Darmstadt, Germany, through its division Merck Serono, initiates the global Phase 3 study of TH-302 in combination with gemcitabine in patients with pancreatic cancer (MAESTRO); Threshold receives $30 million milestone payment.

2012
Phase 2 trial results suggest that TH-302 can be combined with doxorubicin and continued as single agent maintenance treatment for patients with soft tissue sarcoma.
Initial results from Phase 1/2 trial demonstrate TH-302 plus bevacizumab is tolerated in patients with glioblastoma.
Phase 2b trial of TH-302 in pancreatic cancer meets primary endpoint; Threshold earns $20 million milestone payment.
TH-302 receives Orphan Drug Designation for the treatment of soft tissue sarcoma in the U.S. and Europe.
Threshold signs global agreement with Merck KGaA, Darmstadt, Germany, to co-develop TH-302 with an option to co-commercialize in the U.S.; Threshold receives $25 million upfront payment.

2011
Initial results of Phase 1 trial suggest activity of TH-302 in patients with advanced leukemias.
Threshold initiates Phase 3 trial of TH-302 in soft tissue sarcoma.
Initiated three Phase 1 trials of TH-302 in combination with antiangiogenics (sunitinib, pazopanib, and bevacizumab).
Threshold reaches agreement with FDA on a Special Protocol Assessment for planned Phase 3 trial of TH-302 in soft tissue sarcoma.

2010
Threshold initiates randomized, controlled Phase 2b trial of TH-302 in advanced pancreatic cancer.
Phase 1/2  trialresults demonstrate broad anti-tumor activity of TH-302; Threshold plans to advance TH-302 into Phase 2 controlled trial for pancreatic cancer.

2009
Threshold licenses glufosfamide to Eleison Pharmaceuticals.

2008
Threshold initiates a Phase 1/2 trial of TH-302 in soft tissue sarcoma.
Threshold initiates a Phase 1/2 trial of TH-302 in advanced solid tumors.

2007
Threshold initiates clinical testing of TH-302.
Threshold files Investigational New Drug Application (IND) for TH-302.

2006
Development of lonidamine (TH-070) discontinued; Threshold focuses on development of glufosfamide, 2DG, and TH-302, a hypoxia-targeted drug.

2005
Threshold initiates registrational program for treatment of BPH in the U.S.
Threshold initiates Phase 3 clinical trial of lonidamine (TH-070) in Europe and Canada for BPH.
Threshold completes IPO and is listed on the NASDAQ under the stock symbol THLD.

2004
Threshold initiates clinical testing of 2DG.
Threshold initiates Phase 2 clinical trial of lonidamine (TH-070) for treatment of benign prostatic hyperplasia (BPH) at University of Bari, Italy.
Threshold enters into an agreement with Acraf, S.p.a., for the rights to use Acraf’s regulatory documents related to lonidamine.
Threshold enters into a Development Agreement with MediBIC Co. Ltd to develop glufosfamide in various Asian countries.
Threshold initiates Phase 1/2 clinical trial of glufosfamide with gemcitabine for the first-line treatment of solid tumors, including pancreatic cancer.
U.S. FDA grants glufosfamide Fast-Track Status.
Threshold initiates Phase 3 clinical trial of glufosfamide as second-line treatment for pancreatic cancer.

2003
Threshold enters into an agreement with Baxter for the licensing and development of glufosfamide, a cytotoxic agent linked to beta-D-glucose in order to target the glucose transporter system and increase intracellular uptake into tumor cells.

2002
Threshold enters into an exclusive license agreement with Dr. Theodore J. Lampidis and Dr. Waldemar Priebe for a patent application covering the treatment of cancer with 2-Deoxyglucose (2DG) in combination with certain other drugs.

2001
Threshold Pharmaceuticals is founded by George Tidmarsh, M.D., Ph.D., to discover and develop novel cancer therapies based on targeting the tumor microenvironment and unique metabolic properties of tumors.